Alessio Cortellini։ PECATI Results Suggest Prolonged Disease Stabilisation in Pretreated Thymic Tumours
Alessio Cortellini/policlinicocampusbiomedico.it

Alessio Cortellini։ PECATI Results Suggest Prolonged Disease Stabilisation in Pretreated Thymic Tumours

Alessio Cortellini, Consultant Medical Oncologist and Assistant Professor at Campus Bio-Medico University of Rome, shared on X:

“ORR of 25.6%, yet an exceptional median PFS of 22.1 months!

Final phase II PECATI results suggest that lenvatinib and pembrolizumab may provide prolonged disease stabilisation beyond objective responses in pretreated advanced thymic tumours.

Congrats to Jordi Remon and colleagues!”

Title: Final Analysis From PECATI Phase 2 Trial: Lenvatinib in Combination With Pembrolizumab in Pretreated Advanced B3 Thymoma and Thymic Carcinoma

Authors: Jordi Remon, Paolo Bironzo, Nicolas Girard, Laurence Bigay-Game, Oscar Juan-Vidal, Javier de Castro, Noemí Reguart, Laurent Greillier, Sophie Cousin, Eric Dansin, Margarita Majem, Reyes Bernabé, Joaquin Mosquera-Martinez, Marta Díaz, Alba Meya, Daniel Alcalá-López, Alicia García-Sanz, Luisella Righi, Silvia Novello, Benjamin Besse

Read the article

You can also read: Jordi Remon: PECATI Phase 2 Trial Supports Pembrolizumab Plus Lenvatinib in Pretreated Thymic Cancer.

Jordi Remon